Supranormal Myocardial Creatine and Phosphocreatine Concentrations Lead to Cardiac Hypertrophy and Heart Failure | Zendy

Julie Wallis | Zendy; Craig A. Lygate | Zendy; Alexandra Fischer | Zendy; Michiel ten Hove | Zendy; Jürgen E. Schneider | Zendy; Liam SebagMontefiore | Zendy; Dana Dawson | Zendy; Karen Hulbert | Zendy; Wen Zhang | Zendy; Mei Hua Zhang | Zendy; Hugh Watkins | Zendy; Kieran Clarke | Zendy; Stefan Neubauer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Supranormal Myocardial Creatine and Phosphocreatine Concentrations Lead to Cardiac Hypertrophy and Heart Failure

Author(s) -

Julie Wallis,

Craig A. Lygate,

Alexandra Fischer,

Michiel ten Hove,

Jürgen E. Schneider,

Liam SebagMontefiore,

Dana Dawson,

Karen Hulbert,

Wen Zhang,

Mei Hua Zhang,

Hugh Watkins,

Kieran Clarke,

Stefan Neubauer

Publication year - 2005

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.105.572990

Subject(s) - phosphocreatine , medicine , creatine , heart failure , cardiology , cardiac hypertrophy , myocardial hypertrophy , muscle hypertrophy , energy metabolism

Heart failure is associated with deranged cardiac energy metabolism, including reductions of creatine and phosphocreatine. Interventions that increase myocardial high-energy phosphate stores have been proposed as a strategy for treatment of heart failure. Previously, it has not been possible to increase myocardial creatine and phosphocreatine concentrations to supranormal levels because they are subject to tight regulation by the sarcolemmal creatine transporter (CrT).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research